Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06148298 · ClinicalTrials.gov registry record
Cell-Free DNA Chromatin Immunoprecipitation (ChIP) for Diagnosing Cancer
A clinical trial of Cancer of Pancreas, sponsored by University of Central Florida.
- Recruiting
- Registry status
- 24
- Enrollment target
- 1
- Study location
NCT06148298 is a study of Cancer of Pancreas that is actively recruiting participants, run by University of Central Florida. The registered enrollment target is 24 participants, below the 8,369-participant average among 6 other Cancer of Pancreas trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06148298, a study of Cancer of Pancreas, is actively recruiting participants, sponsored by University of Central Florida.
- RECRUITING
- Registry status
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this research is to use chromatin immunoprecipitation, a method used to study protein-DNA interaction, as a tool to diagnose and prognose pancreatic ductal adenocarcinoma in human samples. This is a Non-Human Subject Research study. All participants are de-identified.
Conditions Studied
Interventions
- OTHER Non-Human Subject Research study.
Study Locations (1)
Florida
- University of Central Florida - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-05-24 |
| Est. Completion | 2025-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06148298
The ClinicalTrials.gov registry entry for NCT06148298 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 8,369-participant average among 6 other Cancer of Pancreas trials with a reported enrollment target (100% lower). The listed sponsor is University of Central Florida, which has 91 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer of Pancreas appearing as the primary indexed condition, and to 1 intervention - of which Non-Human Subject Research study. is the first listed.
NCT06148298 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06148298 about?
NCT06148298 is a clinical study titled "Cell-Free DNA Chromatin Immunoprecipitation (ChIP) for Diagnosing Cancer". The goal of this research is to use chromatin immunoprecipitation, a method used to study protein-DNA interaction, as a tool to diagnose and prognose pancreatic ductal adenocarcinoma in human samples. This is a Non-Human Subject Research study. All participants are de-identified.
What is the current status of trial NCT06148298?
This trial is currently recruiting. The enrollment target is 24 participants. The study started on 2023-05-24. Estimated completion is 2025-05.
What conditions does trial NCT06148298 study?
This clinical trial studies the following conditions: Cancer of Pancreas.
What interventions are being tested in trial NCT06148298?
The interventions under investigation include: Non-Human Subject Research study. (OTHER).
Who is sponsoring clinical trial NCT06148298?
This trial is sponsored by University of Central Florida, which has 91 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06148298 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer of Pancreas
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RECRUITING
-
A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
ACTIVE NOT RECRUITING · Phase 1
-
A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation
ACTIVE NOT RECRUITING · Phase 1
-
Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)
COMPLETED · Phase 1
-
Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.